FDA OKs trial of pig livers as dialysis-like treatment for liver failure
U.S. researchers will soon test whether livers from a gene-edited pig could treat people with sudden liver failure — by temporarily filtering their blood so their own organ can rest and maybe heal.
The first-of-its-kind clinical trial has been cleared by the Food and Drug Administration, according to pig producer eGenesis, which announced the step Tuesday with its partner OrganOx.
An estimated 35,000 people in the U.S. are hospitalized each year when their liver suddenly fails. There are few treatment options and death rates as high as 50%. Many don't qualify for a liver transplant or can't get a match in time.
The new study, which is expected to get underway later this spring, is a twist on the quest for animal-to-human organ transplants. Researchers won't transplant the pig liver but instead will attach it externally to study participants.
The liver is the only organ that can regenerate, but the question is whether having the pig's liver filter the patient's blood for several days could give it that chance.
In experiments with four deceased bodies, that 'bridge' attempt showed the pig liver could support some functions of a human liver for two or three days, said Mike Curtis, CEO of Massachusetts-based eGenesis, which genetically modifies pigs so their organs are more humanlike.
The trial will enroll up to 20 patients in intensive-care units who don't qualify a liver transplant, he said. A device made by Britain's OrganOx, currently used to preserve donated human livers, will pump participants' blood through the pig liver.
It's the latest step in attempts to use gene-edited pig organs to save human lives. Pig kidneys from eGenesis and another pig producer, United Therapeutics, are being used in experimental transplants.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medical News Today
17 hours ago
- Medical News Today
Uplizna: Dosage, side effects, uses, interactions, cost, and more
The Food and Drug Administration (FDA) approves prescription drugs such as Uplizna to treat certain conditions. Uplizna may also be used off-label for other conditions. Off-label drug use is when an FDA-approved drug is prescribed for a purpose other than what it's approved for. Uplizna for NMOSD Uplizna is FDA approved to treat NMOSD in certain adults. Specifically, it's used in adults who test positive for an antibody (a type of immune system protein) called anti-aquaporin-4 (AQP4). NMOSD is a long-term autoimmune disorder that damages nerves in your eyes and spinal cord. Autoimmune disorders occur when your immune system mistakenly attacks healthy tissue in your body. With NMOSD, your immune system mistakenly attacks nerve cells in your spinal cord and optic nerves. This stops these nerves from sending messages correctly. Symptoms of NMOSD can include: eye pain vision changes, such as dim or blurry vision pain, tingling, or numbness muscle spasms or weakness trouble walking problems with bladder or bowel control hiccups nausea and vomiting With NMOSD, you typically have periods where your symptoms flare up or worsen. These are called relapses or attacks. They may be followed by periods of remission, where your symptoms get better or go away. Uplizna helps to stop your immune system from attacking your optic nerves and spinal cord. This helps prevent the number and severity of relapses you may have. It may also lower your risk of needing hospital treatment for your symptoms. For this purpose, Uplizna may be prescribed on its own or with other drugs for NMOSD. Examples of other drugs that doctors may prescribe with Uplizna include corticosteroids, such as methylprednisolone (Medrol) and prednisone. Uplizna for IgG4-RD Uplizna is FDA approved to treat IgG4-RD in adults. Doctors may also call this condition IgG4-related sclerosing disease or IgG4-related systemic disease. IgG4-RD is a long-term autoimmune disorder that damages tissues and organs throughout your body. Autoimmune disorders occur when your immune system mistakenly attacks healthy tissue in your body. With IgG4-RD, your immune system mistakenly attacks many different tissues and organs in your body. This can cause widespread inflammation and damage to multiple organs. The organs and tissues most often affected by IgG4-RD include the pancreas, salivary glands, eyes, and tissues around the digestive organs. Other organs affected include the liver, kidneys, lungs, heart, and thyroid. Symptoms of IgG4-RD can vary, depending on what part of the body is affected. They can include: lumps, masses, or swellings dry mouth or eyes bulging eyes shortness of breath belly or back pain weight loss fatigue headaches With IgG4-RD, your symptoms may be ongoing, or they may flare up or get worse from time to time. You may also develop new symptoms if more parts of your body become affected. Flare-ups are also called relapses or attacks. Some people may also have periods of remission, where their symptoms get better or go away for a time. Uplizna helps to stop your immune system from attacking healthy tissues in your body. This helps prevent the number and severity of relapses you may have. For this purpose, Uplizna may be prescribed on its own or with other drugs for IgG4-RD. Examples of other drugs that doctors may prescribe with Uplizna include corticosteroids, such as methylprednisolone (Medrol) and prednisone. Uplizna and children Uplizna is not FDA-approved for any use in children. It's not known if the drug is safe or effective in children.
Scotsman
a day ago
- Scotsman
Over 1,000 yogis set to downward dog at Emirates Arena for largest event of its kind
In just one week over 1,000 yoga enthusiasts will be namaste-ing at the Emirates Arena in Glasgow as part of a World Yoga Day event with renowned PYPT practitioner, Sadhvi Devaditi. Sign up to our daily newsletter – Regular news stories and round-ups from around Scotland direct to your inbox Sign up Thank you for signing up! Did you know with a Digital Subscription to The Scotsman, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads, loyalty rewards and much more. Learn More Sorry, there seem to be some issues. Please try again later. Submitting... Tickets for the event – believed to be the biggest of its kind - are being snapped up quickly with over 900 already reserved, and organisers are encouraging others to secure their spot now and join the movement. The clincher, tickets are completely free. This year's event promises to be the biggest and most dynamic yet, with a live international broadcast from the Emirates Arena. Advertisement Hide Ad Advertisement Hide Ad The event is a major part of Scotland's contribution to World Yoga Day, recognised globally on 21 June. Sunita Poddar, Chairperson of the Patanjali Yog Peeth (Scotland) Trust In the lead-up to the big day, the city is embracing yoga like never before. Free yoga classes will be offered to offices, schools, and community groups across Glasgow and Edinburgh from 16 to 23 June, helping people of all backgrounds experience the physical and mental health benefits of yoga. This special event is hosted by the Consulate General of India, Edinburgh, and Patanjali Yog Peeth (UK) Trust, with support from Glasgow Indians Association The events are designed to introduce people to yoga, celebrate the community spirit of new and experienced yogis across Glasgow, and supports the bringing together of from across Glasgow to celebrate the benefit of yoga. Advertisement Hide Ad Advertisement Hide Ad Sunita Poddar, Chairperson of the Patanjali Yog Peeth (Scotland) Trust, said: 'Yoga is for everyone - it transcends age, background, and ability. 'At PYPT, we are committed to promoting holistic health and wellbeing by reconnecting communities with the ancient wisdom of yoga. Our aim is to inspire positive change, both physically and mentally, and empower individuals to take control of their own wellbeing. 'This celebration at the Emirates Arena is a chance to come together and experience the transformative power of yoga - we welcome everyone to be part of this special day.' Sunita Poddar is the founder and chief executive of Glasgow-based care home group, Oakminster Healthcare. Part of her mission to root her businesses and approach to person-centred resident care in health and wellbeing will see the team of care home wellbeing enablers trained to deliver low-impact yoga sessions for residents across the five care homes in Govan, Kinning Park, Pollokshields, St George's Cross and Knightswood. The PYPT Yoga Event is free, but registration is essential via Eventbrite.
Scotsman
2 days ago
- Scotsman
Biofilm prevention leader Remora announces groundbreaking partnership with global textile chemical innovator
Award-winning Scottish biotechnology company Remora has announced a major milestone in its commercial journey after signing a new long-term licensing agreement with Swiss-based Beyond Surface Technologies (BST) to bring its revolutionary biofilm prevention technology to the global textile market. Sign up to our daily newsletter – Regular news stories and round-ups from around Scotland direct to your inbox Sign up Thank you for signing up! Did you know with a Digital Subscription to The Scotsman, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads, loyalty rewards and much more. Learn More Sorry, there seem to be some issues. Please try again later. Submitting... Award-winning Scottish biotechnology company Remora has announced a major milestone in its commercial journey after signing a new long-term licensing agreement with Swiss-based Beyond Surface Technologies (BST) to bring its revolutionary biofilm prevention technology to the global textile market. The partnership will see BST – a specialist in sustainable textile chemistry – integrate the patented Remora® technology into its green chemical formulations for use across performance apparel, outdoor garments and technical fabrics. Advertisement Hide Ad Advertisement Hide Ad Biofilms – invisible layers of microorganisms that adhere to fabrics – are a widespread issue in the textile sector. On performance garments in particular, they cause persistent odours, staining, and material degradation, even after repeated washing. They also pose risks of skin irritation and contamination. Matthias Foessel, Co-founder and CEO of Beyond Surface Technologies Remora® technology offers a breakthrough solution. Developed using a scientifically engineered molecule inspired by red seaweed's natural defense mechanisms, it prevents biofilm formation at source, without relying on toxic antimicrobial agents. Remora's collaboration with BST will support the sustainable creation of cleaner, fresher and longer-lasting textiles. The technology can be used at multiple stages of the supply chain. Dr Yvonne Davies, Chief Commercial Officer at Remora, said: 'This partnership with BST is a transformational step for Remora and a breakthrough moment for the textile industry. Our Remora® technology offers a sustainable, scientifically proven alternative to toxic biocidal treatments and will help brands tackle persistent odour, staining and material degradation caused by biofilms. 'Through BST's extensive global supply chain relationships and deep expertise in green chemistry, we now have a clear route to market with some of the biggest names in fashion, performance wear and technical textiles. This collaboration doesn't just scale our technology, it unlocks its full potential to support a cleaner, safer and more sustainable future for textiles.' Advertisement Hide Ad Advertisement Hide Ad Matthias Foessel, Co-founder and CEO of Beyond Surface Technologies, said: 'We are excited to bring this remarkable marine-inspired technology for biofilm prevention to the textile industry. It offers a unique way to keep fabrics and garments cleaner and fresher for longer. 'We're very pleased to have signed this collaboration with Remora, based on a Unilever patent portfolio. This partnership marks another important milestone in our mission to advance chemistry with reduced environmental impact - without compromising on performance.' Originally developed through a decade-long R&D collaboration with Unilever and leading UK universities, Remora's technology now has a direct route into commercial textile markets via BST's formulation expertise and global customer network – which includes many of the world's best-known fashion and sportswear brands.
